SCHEMBL861187

SCHEMBL861187

O=C1NC(=O)/C(=C\c2cnn3ccc(Nc4cccc(Cn5ccnc5)c4)nc23)N1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 2/20 0.37
CYP11B1 P15538 7/20 0.35
CYP11B2 P19099 7/20 0.35
ADRA2C P18825 1/20 0.35
EGFR P00533 2/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TBXAS1 P24557 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
PKM P14618 1/20 0.35
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
PGGT1B P53609 1/20 0.34
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL861188 1.00 CSNK2A2 (0.37) CSNK2A2CSNK2BCYP11B1CYP11B2ADRA2C
SCHEMBL12978998 1.00 CSNK2A2 (0.37) CSNK2A2CSNK2BCYP11B1CYP11B2ADRA2C
SCHEMBL14679088 0.87 CSNK2A2 (0.38) CSNK2A2CYP11B1CYP11B2ADRA2CEGFR
SCHEMBL860054 0.84 CYP11B1 (0.41) CSNK2A2CYP11B1CYP11B2ADRA2CEGFR
SCHEMBL860412 0.84 CSNK2B (0.38) CSNK2A2CSNK2BJAK2JAK1KDM4E
SCHEMBL12979187 0.84 CSNK2B (0.38) CSNK2A2CSNK2BJAK2JAK1KDM4E
SCHEMBL860413 0.84 CSNK2B (0.38) CSNK2A2CSNK2BJAK2JAK1KDM4E
SCHEMBL13020870 0.83 JAK3 (0.40) CSNK2A2CSNK2BJAK2KDM4EALDH1A1
SCHEMBL860165 0.83 JAK3 (0.40) CSNK2A2CSNK2BJAK2KDM4EALDH1A1
SCHEMBL860166 0.83 JAK3 (0.40) CSNK2A2CSNK2BJAK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 CSNK2A2 74/4885CSNK2B 71/4885CYP11B1 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.